Liminatus Pharma Warrants Common Stock

Liminatus Pharma Warrants posts a common stock of $550M as of March 2022. That compares with $240M in the prior-year period — up 126.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Liminatus Pharma Warrants's common stock was $240M. The latest reading is $550M — a 126.8% year-over-year increase (period ending March 2022). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Liminatus Pharma Warrants's financial statement story. At $550M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LIMNW's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Liminatus Pharma Warrants's other metric pages and overview cover the third.